TrialPharmacology research & perspectives2024

Clinical pharmacology and tolerability of REC-994, a redox-cycling nitroxide compound, in randomized phase 1 dose-finding studies.

Ron Alfa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.